About BONIVA® ibandronate sodium

One tablet. Once a month.

Choose BONIVA

When a bisphosphonate is appropriate for postmenopausal osteoporosis
Ask your newly diagnosed and current bisphosphonate patients if they would prefer once-monthly dosing

Delivers bisphosphonate efficacy*
Offers the convenience of monthly dosing
- Instruct patients to take with water on an empty stomach upon rising in the morning, and to remain upright and in fasting state for at least 60 minutes... only once-monthly
Tolerability profile
- BONIVA 150 mg monthly similar to daily dose
- BONIVA 2.5 mg daily similar to placebo

Prescribe BONIVA 150 mg Tablet once a month

*BONIVA is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

BONIVA is contraindicated in patients unable to stand or sit upright for at least 60 minutes or with uncorrected hypocalcemia.

BONIVA is contraindicated in patients with known hypersensitivity to BONIVA or any of its components.

Read full Prescribing Information.

Important Safety Information for BONIVA Tablets
BONIVA Tablets are indicated for the treatment and prevention of postmenopausal osteoporosis. BONIVA is contraindicated in patients unable to stand or sit upright for at least 60 minutes or with uncorrected hypocalcemia. BONIVA is contraindicated in patients with known hypersensitivity to BONIVA or any of its components. Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy. Adequate intake of calcium and vitamin D is important in all patients. BONIVA is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min). Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Additionally, osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures.

BONIVA, like other bisphosphonates administered orally, may cause upper gastrointestinal (GI) disorders such as dysphagia, esophagitis and esophageal or gastric ulcer. As aspirin, NSAIDs and bisphosphonates are associated with GI irritation, caution should be exercised when using them concomitantly. The overall adverse events profile of BONIVA 2.5 mg daily was similar to that of placebo. In a one-year study comparing BONIVA 150 mg once-monthly and BONIVA 2.5 mg daily, the overall incidence of adverse events with the two dosing regimens was similar. The most commonly reported adverse events (≥5%) regardless of causality were abdominal pain (BONIVA 150 mg 7.8% vs BONIVA 2.5 mg 5.3%), hypertension (6.3% vs 7.3%), dyspepsia (5.6% vs 7.1%), arthralgia (5.6% vs 3.5%), nausea (5.1% vs 4.8%) and diarrhea (5.1% vs 4.1%).

GlaxoSmithKline